About Us


About ADC Therapeutics

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our proprietary ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer platform providing a superior therapeutic index compared to first- generation PBD ADCs. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Our programs, including ADCT-402, ADCT-301, ADCT-602, ADCT-601 and our partnered program MEDI3726, are advancing in ongoing clinical trials in multiple hematological and solid tumor indications. In addition, we have numerous preclinical ADCs that we are working to bring to the clinic.

ADC Therapeutics was founded in 2012, and we have raised $455 million since that time to advance our pipeline of programs. We are based in Lausanne, Switzerland and have operations in London (R&D), New Jersey (Clinical) and San Francisco (CMC).

The team at ADC Therapeutics has a deep understanding of ADCs and the oncology treatment landscape. We are dedicated to efficiently progressing our potential best-in-class PBD-armed ADCs to address significant unmet medical needs and improve outcomes for people with difficult-to-treat cancer.